A psychopath lacks empathy just like a person with frontal head injury, study suggests

ScienceDaily (Jan. 25, 2011) — People diagnosed as psychopathic have difficulty showing empathy, just like patients who have suffered frontal head injury. This has been shown in a new study from the University of Haifa. "Our findings show that people who have psychopathic symptoms behave as though they are suffering frontal brain damage," said Dr. Simone Shamay-Tsoory, who conducted the study.

See Also:Mind & BrainBrain InjuryIntelligenceDisorders and SyndromesNeurosciencePsychologyBehaviorReferenceEmpathyAntisocial personality disorderEmotional detachmentBrain damage

Psychopathy is a personality disorder that finds expression in extreme anti-social behavior and intentional harm to others, including a lack of compassion and empathy. An existing explanation for such behavior suggests inability to comprehend the existence of emotions in others. However, the fact that many psychopaths act with sophistication and deceit with intention to harm others, indicates that they actually have a good grasp of the mental capacity of others -- and are even capable of using that knowledge in order to cause them harm.

Earlier research by Dr. Shamay-Tsoory has examined individuals with frontal head injury, i.e., damage to parts of the brain that are responsible for emotional functioning. She has shown that people suffering this type of brain damage have difficulty showing empathy. Having observed similar emotional deficiency in psychopathic behavior, she set out to see if there is in fact a similarity between the two cases.

The current study assessed 17 people who had been diagnosed by psychiatrists as psychopathic -- and not suffering from any known brain damage; and another 25 individuals suffering frontal lobe injury. Each of the participants underwent a computerized test examining cognitive ability to recognize feelings in another and the ability to demonstrate empathy for another's emotions. They were also tested to gage their capacity to understand another's thoughts. The results of these tests showed that both groups demonstrated a similar difficulty in showing empathy, while two control groups of individuals with no known mental disorders or brain damage and individuals with non-frontal brain damage both showed different results with positive empathy capabilities.

"Seeing as psychopathic behavior is similar to that of a person with brain damage, it could be that it could benefit from similar forms of treatment," Dr. Shamay-Tsoory noted.

Email or share this story:

Vehicle pollution significantly damages the brain, mouse study suggests

ScienceDaily (Apr. 13, 2011) — If mice commuted, their brains might find it progressively harder to navigate the maze of Los Angeles freeways. A new study reveals that after short-term exposure to vehicle pollution, mice showed significant brain damage -- including signs associated with memory loss and Alzheimer's disease.

See Also:Health & MedicineBrain TumorNervous SystemHealthy AgingMind & BrainIntelligenceBrain InjuryNeuroscienceLiving WellStrange ScienceReferenceSensory neuronStem cell treatmentsBrain damageDementia with Lewy bodies

The mind-numbing toxin is not an exhaust gas, but a mix of tiny particles from burning of fossil fuel and weathering of car parts and pavement, according to the study to be published April 7 in the journal Environmental Health Perspectives.

Many studies have drawn a link between vehicle pollution and health problems. This is the first to explore the physical effect of freeway pollution on brain cells.

The authors found a way to recreate air laden with freeway particulate matter inside the laboratory. Whether in a test tube or in live mice, brain cells showed similar responses:

Neurons involved in learning and memory showed significant damage, The brain showed signs of inflammation associated with premature aging and Alzheimer's disease, Neurons from developing mice did not grow as well.

The freeway particles measured between a few dozen to 200 nanometers -- roughly one-thousandth the width of a human hair, and too small for car filtration systems to trap.

"You can't see them, but they are inhaled and have an effect on brain neurons that raises the possibility of long-term brain health consequences of freeway air," said senior author Caleb Finch, an expert in the effects of inflammation and holder of the ARCO/William F. Kieschnick Chair in the Neurobiology of Aging.

Co-author Constantinos Sioutas, of the USC Viterbi School of Engineering, developed the unique technology for collecting freeway particulates in a liquid suspension and recreating polluted air in the laboratory. This made it possible to conduct a controlled study on cultured brain cells and live animals.

Exposure lasted a total of 150 hours, spread over 10 weeks, in three sessions per week lasting five hours each.

"Of course this leads to the question, 'How can we protect urban dwellers from this type of toxicity?' And that's a huge unknown," Finch said.

The authors hope to conduct follow-up studies on issues such as:

Memory functions in animals exposed to freeway particulates, Effects on development of mice exposed prenatally, Lifespan of exposed animals, Interaction of particulates with other components of smog, such as heat and ozone, Potential for recovery between periods of exposure, Comparison of effects from artificially and naturally occurring nanoparticles, Chemical interactions between freeway particulates and brain cells.

If further studies confirm that freeway particulates pose a human health hazard, solutions will be hard to find.

Even an all-electric car culture would not solve the problem on its own, Finch said.

"It would certainly sharply decrease the local concentration of nanoparticles, but then at present electrical generation still depends upon other combustion processes -- coal -- that in a larger environment contribute nanoparticles anyway.

"It's a long-term global project to reduce the amount of nanoparticles around the world. Whether we clean up our cars, we still have to clean up our power generation."

Email or share this story:

Viagra could reduce multiple sclerosis symptoms, study suggests

ScienceDaily (May 19, 2011) — Universitat Autònoma de Barcelona researchers have discovered that Viagra®  (sildenafil) drastically reduces multiple sclerosis symptoms in animal models with the disease. The research, published in Acta Neuropathologica, demonstrates that a practically complete recovery occurs in 50% of the animals after eight days of treatment. Researchers are confident that clinical trials soon will be carried out in patients given that the drug is well tolerated and has been used to treat sexual dysfunction in some multiple sclerosis patients.

See Also:Health & MedicineMultiple Sclerosis ResearchDiseases and ConditionsAlzheimer's ResearchMind & BrainMultiple SclerosisDisorders and SyndromesAlzheimer'sReferenceMyelinAxonSexual dysfunctionErectile dysfunction

Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and one of the main causes of disability among young adults. The disease is caused by the presence of multiple focuses of demyelination (loss of myelin sheaths around the axons, affecting the ability of neurons to communicate) and neurodegeneration in different areas of the central nervous system. There is currently no cure for the disease, although some drugs have proven effective in fighting symptoms and preventing it from progressing.

A research team from the UAB Institute of Biotechnology and Biomedicine directed by Dr Agustina García, in collaboration with the research team directed by Dr Juan Hidalgo from the UAB Institute of Neurosciences, has studied the effects of a treatment using sildenafil, sold as Viagra®, in an animal model of multiple sclerosis known as experimental autoimmune encephalomyelitis (EAE). Researchers demonstrated that a daily treatment with sildenafil after disease onset quickly reduced clinical signs, with a practically complete recovery in 50% of the cases after eight days of treatment. Scientists observed how the drug reduced the infiltration of inflammatory cells into the white matter of the spinal cord, thus reducing damage to the nerve cell's axon and facilitating myelin repair.

Sidenafil, together with tadalafil (Cialis®) and vardenafil (Levitra®), form part of a group of vasodilator drugs known as phosphodiesterase type 5 (PDE5) inhibitors, used in the treatment of erectile dysfunction and pulmonary arterial hypertension. Recent studies in animal models of central nervous system pathologies already pointed to the fact that in addition to vasodilation, these drugs could contain other neuroprotective actions and suggest their usefulness as possible treatments of both acute (cerebrovascular stroke) and chronic (Alzheimer's) neuropathologies.  Research published in 2010 in the Journal of Neurochemistry by the same research group from UAB demonstrated that one of these inhibitors reduced neuroinflammation and neuronal damage in animal models of traumatic brain injury.

Email or share this story: